Tag: healthcare
Amgen Stock Analysis: Buy or Sell? Valuation, Cash Flow & Debt
Amgen (AMGN) is rated Hold because strong cash generation supports the business, but the valuation already reflects much of that quality. The key concern is elevated debt and policy-driven pricing pressure, which limit upside despite a 35.6% operating margin and solid free cash flow.
Boston Scientific Stock Analysis: Buy or Sell? Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside. The key question is whether BSX can keep growing fast enough to justify 13.4x EV/EBITDA while managing a $12.6B debt load.
PACS Group Stock Analysis: Buy or Sell? Leverage, Valuation & Growth
PACS Group Inc. (PACS) is rated Hold as growth remains solid but leverage keeps the stock from looking cheap. Revenue is expanding, yet the balance sheet is stretched with high debt and a weak current ratio.
Oscar Health Stock Analysis: Buy or Sell? Valuation, Margins & Cash Flow
Oscar Health (OSCR) is rated Hold as rapid revenue growth and strong free cash flow are offset by uneven margins and meaningful debt. The stock looks reasonably priced, but the earnings base still needs more proof before the upside case is fully convincing.
Zoetis Stock Analysis: Buy or Sell? Valuation, Margins & Growth
Zoetis (ZTS) is rated Hold because its premium margins and cash generation are solid, but revenue growth remains essentially flat. The stock looks fairly valued to slightly rich unless sales growth re-accelerates and supports a higher multiple.
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just $27.1 million of year-end cash leave little room for delay before clinical proof arrives.
Lantheus Stock Analysis: Buy or Sell? Valuation, Margins & Growth
Lantheus (LNTH) is rated Hold because strong cash generation and a low-debt balance sheet are offset by uneven quarterly revenue growth. Its 24.1x trailing P/E and 16.9x EV/EBITDA leave less room for disappointment.
Nutex Health Stock Analysis: Buy or Sell? Free Cash Flow, Valuation, Reimbursement Risk
Nutex Health Inc. (NUTX) is rated Buy in this stock analysis because it is already turning revenue into strong free cash flow, with a 15.6% FCF yield and 19.2% FCF margin. The key risk is reimbursement and arbitration exposure, which could pressure earnings if disputed claims stay elevated.
Stereotaxis Stock Analysis: Buy or Sell? Cash Burn, Revenue, Valuation & Margins
Stereotaxis (STXS) is rated Sell as uneven revenue and ongoing cash burn outweigh the platform’s gross-margin potential. A 4.6x EV/revenue multiple looks demanding while levered free cash flow remains negative, keeping dilution and execution risk front and center.
Clover Health Stock Analysis: Buy or Sell? Valuation & Margins, Cash Flow
Clover Health Investments Corp. (CLOV) is rated Hold after its first profitable quarter, but trailing margins and free cash flow still lag. The business needs sustained revenue and EBITDA improvement before the new inflection looks durable.